Literature DB >> 32195681

Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer.

Mohammad Amin Hadavand1, Dirk Mayer2,3, Wengen Chen2, Amelia Wnorowski2, Mohummad Minhaj Siddiqui1,3,4.   

Abstract

PURPOSE OF REVIEW: The present review describes the current role of metabolic imaging techniques such as multiparametric MRI (mpMRI), magnetic resonance spectroscopic imaging (MRSI), hyperpolarized MRSI, and positron emission tomography (PET) in the diagnosis of primary prostate cancer, surveillance of low-grade disease, detection of metastases, and evaluation of biochemical recurrence after therapy. RECENT
FINDINGS: The natural history of prostate cancer ranges from indolent disease that is optimally monitored by active surveillance, to highly aggressive disease that can be lethal. Current diagnostic methods remain imperfect in noninvasively distinguishing between silent versus aggressive tumors. Hence, there is a high demand for noninvasive imaging techniques that offer insight into biological behavior of prostate cancer cells. Characterization of prostate cancer metabolism is a promising area to provide such insights.
SUMMARY: Metabolic imaging may allow for greater detection and ultimately characterization of tumor based on aggressiveness and spread. Hence, it has the potential to monitor tumor activity, predict prognostic outcomes, and guide individualized therapies.

Entities:  

Mesh:

Year:  2020        PMID: 32195681      PMCID: PMC7328528          DOI: 10.1097/CCO.0000000000000625

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  2 in total

1.  How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?

Authors:  Lawrence D True; Delphine L Chen
Journal:  Clin Cancer Res       Date:  2021-04-23       Impact factor: 12.531

2.  Identification of novel prostate cancer genes in patients stratified by Gleason classification: Role of antitumoral genes.

Authors:  Elisa Díaz de la Guardia-Bolívar; Rocío Barrios-Rodríguez; Igor Zwir; José Juan Jiménez-Moleón; Coral Del Val
Journal:  Int J Cancer       Date:  2022-03-18       Impact factor: 7.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.